Ca-AKG and inflammation: the SASP, cytokines and inflammaging picture

Ca-AKG has a real inflammation story, but it is not a simple “anti-inflammatory supplement” story. AKG changes immune-cell metabolism, senescence signaling and inflammatory pathways in several experimental systems. Some of those effects are anti-inflammatory; others are context-dependent and can increase specific inflammatory signals.

No completed randomized human trial has yet shown that oral Ca-AKG lowers systemic inflammatory biomarkers in healthy adults. That is the key evidence boundary.

For the broader evidence, see the Ca-AKG evidence guide. For the senescence mechanism, see how Ca-AKG works.

What is inflammaging?

Inflammaging describes the chronic, low-grade inflammatory state that tends to increase with age. It involves changes in immune-cell function, senescent-cell signaling, tissue damage, metabolic stress and altered cytokine networks.

One contributor is the senescence-associated secretory phenotype (SASP): inflammatory cytokines, chemokines and proteases released by some senescent cells.

Reducing SASP output without killing the senescent cell is often described as a senomorphic effect. That is a better fit for the key Ca-AKG evidence than calling Ca-AKG a senolytic.

What did the 2020 Ca-AKG mouse study show?

The 2020 Cell Metabolism study measured both circulating inflammatory markers in mice and SASP output in senescent human fibroblasts [1].

In female mice, Ca-AKG suppressed a 24-marker inflammatory cytokine/chemokine panel at 24 months. The same clear pattern was not demonstrated in males. The study also reported higher frequencies of IL-10-producing CD4+ and CD8+ T cells in treated females.

In senescent IMR-90 fibroblasts, AKG reduced expression of several SASP genes and lowered IL-6 secretion without eliminating the senescent phenotype itself.

That is why the paper supports a senomorphic-like interpretation: lower inflammatory output from senescent cells, not senescent-cell clearance.

The AKG–TET pathway adds a mechanistic explanation

A 2025 cell study linked AKG availability to TET enzyme activity, DNA methylation state, oxidative stress, NF-κB activation and IL-6/IL-8 secretion in human fibroblasts and peripheral blood mononuclear cells [2].

Reducing AKG-TET activity reproduced multiple senescence features. Experimentally restoring that axis reversed several markers in vitro.

The important limitation is that the study used engineered peptides and genetic tools, not oral Ca-AKG. It strengthens the biological mechanism; it does not show that a supplement reproduces the effect in a person.

Macrophages: AKG can shift inflammatory programming

A 2017 immunometabolism study showed that AKG helped drive macrophages toward an M2-like metabolic and epigenetic program and that the AKG-to-succinate balance influenced inflammatory phenotype [3].

This is important because it links metabolism directly to immune-cell behavior. But macrophage polarization in laboratory systems is not the same as proving lower CRP, IL-6 or inflammatory disease activity after oral Ca-AKG in humans.

Diabetes and thromboinflammation: supportive but not oral human evidence

A 2023 study added a disease-specific line of evidence. Dietary AKG reduced platelet and leukocyte activation, circulating IL-1β, TNF-α and IL-6, and lung inflammatory changes in diabetic mice [4].

The researchers also exposed blood from people with type 2 diabetes to octyl-AKG ex vivo and observed reduced aggregation and thrombus formation.

This is translationally interesting, but the human component happened outside the body. It does not establish that a person with diabetes who swallows Ca-AKG will achieve the same anti-inflammatory or antithrombotic effect.

Human immune-cell studies show the story is not uniformly anti-inflammatory

This is one of the most important corrections to simplistic Ca-AKG marketing.

A 2024 study of human monocyte-derived dendritic cells found that exogenous AKG reduced several inflammatory maturation features and reduced Th1 induction, while increasing tolerogenic/regulatory characteristics [5].

At the same time, AKG increased IL-1β in some conditions and could enhance Th17 polarization.

A 2026 study of human monocyte-derived myeloid suppressor cells likewise found mixed effects: AKG increased suppressive/regulatory activity, but also increased IL-1β and Th17-promoting activity after stimulation [6].

Those papers make the biological picture more realistic: AKG is an immunometabolic regulator, not a universal cytokine suppressor. Cell type, activation state, redox environment and disease context matter.

What does the oxidative-stress evidence add?

An older mouse study found that Ca-AKG improved plasma antioxidant status, reduced lipid-peroxidation markers and improved ex-vivo aortic elastic recoil in aged mice [7].

Oxidative stress and inflammation interact closely, so this is supportive biology. It did not directly test a human inflammatory outcome.

Is Ca-AKG good for arthritis?

There is now preclinical evidence relevant to joint inflammation, but no human Ca-AKG arthritis trial.

A 2024 study found that AKG improved cartilage pathology in aged mice and in a surgically induced rat temporomandibular-joint osteoarthritis model, with lower senescence/catabolic signaling linked to IKK/NF-κB suppression [8].

That overturns the older statement that there is “no animal arthritis evidence.” There is animal evidence now.

What we still do not have is evidence that oral Ca-AKG relieves pain, improves function or slows structural arthritis progression in people.

Has oral Ca-AKG lowered inflammatory markers in a completed human trial?

Not in the published outcome literature in our audited corpus.

ABLE is a randomized, placebo-controlled Ca-AKG trial with a broader biomarker and healthspan program, but the published documents currently consist of the protocol and recruitment analysis rather than treatment outcomes [9].

So the human evidence today is mechanistic human-cell work, ex-vivo human blood work and observational/clinical context—not a completed oral Ca-AKG trial demonstrating lower systemic inflammation.

Does this make Ca-AKG a senolytic?

No.

The strongest direct Ca-AKG senescence evidence shows altered SASP output and inflammatory signaling rather than selective killing of senescent cells. “Senomorphic-like” is a more accurate description of that experimental effect.

For comparison with a true senolytic strategy, see Ca-AKG and fisetin.

Bottom line

Ca-AKG has a credible immunometabolic and senescence-related inflammation story, but the direction of effect depends on biological context.

The strongest evidence includes SASP suppression and cytokine changes in the 2020 mouse/cell study, AKG–TET senescence biology, macrophage reprogramming, reduced thromboinflammation in diabetic mice, and newer human immune-cell studies. Those newer immune-cell papers are especially important because they show that AKG can also increase IL-1β or Th17-related signaling in specific conditions.

So “Ca-AKG reduces inflammation” is too broad. The defensible 2026 statement is: AKG modulates inflammatory and immune pathways in multiple experimental systems, but a clinically meaningful anti-inflammatory effect from oral Ca-AKG in humans has not been established.